Home / Leaderboard / Rock Springs Capital Management LP
Rock Springs Capital Management LP
Kris Jenner · Hedge Fund · Long/Short Equity
Rock Springs Capital Management LP is a Baltimore-based investment firm founded in 2013 by Kris Jenner, Mark Bussard, and David Ssekimauri, former leaders of the healthcare team at T. Rowe Price. The firm specializes exclusively in the healthcare and life sciences sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services. Leveraging the deep clinical and scientific backgrounds of its partners, the firm manages capital for institutional and private clients through a research-intensive approach. Rock Springs is known for identifying high-conviction opportunities across various stages of company development, from early-stage private ventures to large-cap public corporations, primarily through its specialized hedge fund strategies.
Simulated Performance
| Metric | Value |
|---|---|
| Total return | +59.1% |
| YTD return | +9.9% |
| Sharpe ratio | 4.78 |
| Win rate | 49% |
| AUM | $1.3B |
| Inception | Oct 1, 2025 |
| Updated | Sep 18, 2026 |
Institution Status
| Field | Value |
|---|---|
| AUM | $1.3B |
| Turnover | Low (<15%) |
| Avg holding | 18 Months |
| Inception | Oct 1, 2025 |
| Website | http://www.rockspringscapital.com |
Current Holdings
Updated on Sep 18, 2026.
| Ticker | Name | Portfolio % | Return |
|---|---|---|---|
| RVMD | Revolution Medicines Inc | 18.6% | +92.2% |
| TVTX | Travere Therapeutics Inc | 11.2% | +44.9% |
| LLY | Eli Lilly and Company | 8.8% | +24.3% |
| MDGL | Madrigal Pharmaceuticals Inc | 7.4% | +10.5% |
| MIRM | Mirum Pharmaceuticals Inc | 6.4% | +5.3% |
| RYTM | Rhythm Pharmaceuticals Inc | 5.6% | -2.6% |
| KYMR | Kymera Therapeutics Inc | 4.3% | +63.0% |
| ARGX | argenx NV ADR | 4.2% | +25.3% |
| INSM | Insmed Inc | 3.6% | -14.3% |
| ASND | Ascendis Pharma AS | 3.6% | -4.1% |
| XENE | Xenon Pharmaceuticals Inc | 3.2% | -9.5% |
| SRRK | Scholar Rock Holding Corp | 3.2% | +11.8% |
| PEN | Penumbra Inc | 2.9% | +11.2% |
| MMED | MiniMed Group, Inc. Common Stock | 2.8% | +8.2% |
| THC | Tenet Healthcare Corporation | 2.6% | +12.4% |
| IRTC | iRhythm Technologies Inc | 2.6% | -6.2% |
| DXCM | DexCom Inc | 2.3% | +5.9% |
| HTFL | Heartflow, Inc. Common Stock | 2.3% | +3.4% |
| CLDX | Celldex Therapeutics Inc | 2.2% | +2.1% |
| GPCR | Structure Therapeutics Inc. American Depositary Shares | 2.2% | -2.5% |
Recent activity
| Date | Action | Ticker | Weight |
|---|---|---|---|
| Sep 14, 2026 | BUY | CLDX | 0.0% → 2.2% |
| Sep 14, 2026 | SELL | HTFL | 2.2% → 2.3% |
| Sep 14, 2026 | SELL | THC | 2.6% → 2.6% |
| Sep 14, 2026 | BUY | IRTC | 2.6% → 2.6% |
| Sep 14, 2026 | SELL | TVTX | 11.3% → 11.2% |
Investment Style Analysis
Rock Springs Capital Management LP is widely recognized for employing a Long/Short Equity strategy. As of Sep 18, 2026, the firm oversees approximately $1.3B in assets under management (AUM). The portfolio demonstrates a clear preference for the Biotechnology and Drug Manufacturers - General sectors, reflecting a high-conviction approach to capital allocation.
Recent Market Moves
During the latest rebalancing period ending Sep 14, Rock Springs Capital Management LP made a significant move by increasing exposure to CLDX. This adjustment aligns with the fund's dynamic approach to risk management and capital deployment in current market conditions.
Investment Philosophy
Rock Springs Capital employs a fundamental, bottom-up investment philosophy focused on the global healthcare and life sciences industries. The firm integrates medical and financial expertise to conduct rigorous scientific due diligence, evaluating therapeutic efficacy, regulatory risk, and commercial potential. Their strategy typically involves a long/short equity approach, targeting companies that address significant unmet medical needs or offer transformative technological innovations. By maintaining a concentrated portfolio and engaging in both public and private markets, the firm seeks to generate superior risk-adjusted returns through deep domain knowledge and a long-term perspective on clinical and market milestones.
Disclaimer
The content provided on this page, including the simulated portfolio performance, holdings analysis, and AI-generated insights, is for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. All data is derived from historical SEC 13F filings and other public disclosures, which have a reporting lag. The "Simulated Performance" is a hypothetical reconstruction based on past disclosures and does not represent the actual returns of the institution. Past performance is not indicative of future results. Tritonix.ai is not affiliated with Rock Springs Capital Management LP.
Similar Investment Style
Based on Long/Short Equity.
- Perceptive Advisors LLC — Joseph Edelman · 3M +12.3%
- Glenview Capital Management, LLC — Larry Robbins · 3M +8.2%
- Zweig-DiMenna Associates, Inc. — Joseph DiMenna · 3M -1.6%
- Redmile Group, LLC — Jeremy Green · 3M +7.5%
Frequently asked questions
How is the simulated portfolio for Rock Springs Capital Management LP constructed?
This simulation is powered by Tritonix AI using official SEC filings. We focus on the "Best Ideas" by filtering for only the Top 20 largest holdings and rebalancing them to 100%. The simulation tracks performance starting from Oct 1, 2025. Our AI monitors for updates every Monday to capture major shifts. This concentrated approach highlights the manager's true stock-picking skill and mirrors their actual investment returns.
What is Rock Springs Capital Management LP's largest holding?
As of the latest filing, Rock Springs Capital Management LP's top position is Revolution Medicines Inc (RVMD), representing 18.6% of the portfolio. This reflects a high-conviction bet by the institution.
What is Rock Springs Capital Management LP's historical performance and risk profile?
Our simulation indicates a total return of +59.1% with a win rate of 49%. Notably, the portfolio maintains a Sharpe Ratio of 4.78, suggesting an exceptional level of risk-adjusted returns compared to the broader market.
What sectors does Rock Springs Capital Management LP primarily invest in?
Rock Springs Capital Management LP has a strong preference for the Biotechnology sector, which makes up 75.8% of their disclosed assets. The portfolio also has exposure to Drug Manufacturers - General, indicating a specific thematic focus.
Is Rock Springs Capital Management LP's portfolio concentrated or diversified?
Rock Springs Capital Management LP runs a moderately concentrated portfolio with 20 disclosed positions. The top 3 holdings alone account for 38.6% of the total portfolio weight, suggesting a strategy that favors broader market exposure.
How has Rock Springs Capital Management LP performed in 2026?
Our AI-simulated model portfolio for Rock Springs Capital Management LP tracks a Year-to-Date (YTD) return of +9.9%. This metric helps investors gauge the institution's effectiveness in the current market environment.
Does Kris Jenner manage Rock Springs Capital Management LP directly?
Yes, Kris Jenner serves as the key portfolio manager for Rock Springs Capital Management LP, overseeing the investment strategy and final capital allocation decisions.